Structured abstract
Background In the wake of the 2022-2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks.
Aim This study combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate the risk of future mpox outbreaks among men who have sex with men (MSM).
Methods Serum samples were obtained from 1,065 MSM visiting the Centres for Sexual Health (CSH) in Rotterdam or Amsterdam after the introduction of vaccination and the peak of the Dutch mpox outbreak. For MSM visiting the CSH in Rotterdam, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)- specific IgG. These observations were combined with literature data on infection dynamics and vaccine effectiveness to inform a stochastic transmission model to estimate the risk on future mpox outbreaks.
Results The seroprevalence of VACV-specific antibodies was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Transmission modelling showed that the impact of risk group vaccination on the original outbreak was likely small; however, the number of mpox cases in a future outbreak would be markedly reduced because of vaccination. Simultaneously, the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis will be a key component of any strategy to prevent new outbreaks.
Discussion Our findings indicate a reduced likelihood of future mpox outbreaks among MSM in the Netherlands under the current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities, and disease awareness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by HORIZON-HLTH-2022-MPX-14 (101115188). RIVM-CIb (National Institute for Public Health and the Environment-Centre for Infectious Disease Control) provided funding for serological testing. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Prior to the study, we obtained approval from the Erasmus MC Medical Ethics Review Committee (MEC-2022-0675) granting permission to conduct research using residual materials. The AmsterdamUMC Medical Ethics Review committee granted permission for samples from Amsterdam (W22_428#22.506). A privacy impact assessment was made for combining data from the CSH Rotterdam clients, including vaccination indication and infection status, with their vaccination data. No additional data or samples were collected specifically for this study and all samples were pseudonymised, ensuring that no identifiable data from participants were collected, transferred, or analysed. This study did not involve any direct interaction with participants or any potential harm.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
Deidentified individual participant data, the analytics code, and other supporting documents will be made available when the study is complete, upon requests made to the corresponding author.
